Kissei out-licenses linzagolix in Taiwan

Japanese drugmaker Kissei Pharmaceutical (TYO: 4547) has entered into a license agreement with Synmosa Biopharma for the development and commercialization rights in Taiwan for the GnRH antagonist linzagolix that was discovered by Kissei.

Under the terms of the accord, Synmosa will develop and commercialize linzagolix in Taiwan. Kissei will receive an undisclosed upfront payment, milestones based on the progress of the development conducted and royalty payments according to the sales of product by Synmosa. The upfront income is triggered by this agreement, and it has negligible effects on Kissei's consolidated business forecasts for the fiscal year ending in March 2023.

Linzagolix is a novel, orally administered GnRH (gonadotropin releasing hormone) receptor antagonist. Linzagolix acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropin. Ultimately reducing estrogen production at the ovaries, it improves symptoms of uterine fibroids and endometriosis.